BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2020 5:49:13 AM | Browse: 663 | Download: 792
 |
Received |
|
2020-05-06 05:53 |
|
Peer-Review Started |
|
2020-05-06 05:53 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-15 06:53 |
|
Revised |
|
2020-05-21 11:26 |
|
Second Decision |
|
2020-07-29 11:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-08-01 21:42 |
|
Articles in Press |
|
2020-08-01 21:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-05 17:26 |
|
Typeset the Manuscript |
|
2020-08-22 10:47 |
|
Publish the Manuscript Online |
|
2020-08-26 05:49 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Opinion Review |
| Article Title |
Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Phuc Van Pham and Ngoc Bich Vu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Phuc Van Pham, PhD, Associate Professor, Director, Lecturer, Senior Scientist, Stem Cell Institute, VNU-HCM University of Science, Ho Chi Minh city, Viet Nam, 227 Nguyen Van Cu, District 5, Ho Chi Minh City, Viet Nam, Ho Chi Minh City 08000, Viet Nam. pvphuc@hcmuns.edu.vn |
| Key Words |
Coronavirus; COVID-19; Mesenchymal stem cells; Umbilical cord derived mesenchymal stem cells; ; |
| Core Tip |
Based on the biological characteristics of mesenchymal stem cells, especially umbilical cord-derived mesenchymal stem cells (UC-MSCs), and the first clinical trial using MSCs for Coronavirus disease-2019 (COVID-19) treatment, we discuss the use of UC-MSCs to improve COVID-19 symptoms. UC-MSCs are suitable therapeutic candidates for COVID-19. Indeed, they are the strongest immunomodulatory MSCs and exhibit low immunogenicity compared with bone marrow-derived MSCs, adipose tissue-derived MSCs, and other MSCs. UC-MSCs are easily collected and expanded in vitro with minimal ethical concerns. In summary, UC-MSCs can be used to improve severe-stage COVID-19 patient symptoms by suppressing inflammation and stimulating wound healing. |
| Publish Date |
2020-08-26 05:49 |
| Citation |
Pham PV, Vu NB. Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations. World J Stem Cells 2020; 12(8): 721-730 |
| URL |
https://www.wjgnet.com/1948-0210/full/v12/i8/721.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v12.i8.721 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
